Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.
Zacks Investment Research on MSN5d
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract InfectionGSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract ...
Novartis has unveiled a dazzling multi-billion dollar business deal which sees it divest its vaccines and animal health divisions, build its oncology portfolio, and create a new joint venture ...
We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...
GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback